Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials
Source abstract
Abstract
With the reason that systemically administered adenovirus (Ad) is rapidly extinguished by innate/adaptive immune responses and accumulation in liver, in vivo application of the Ad vector is strictly restricted. For achieving to develop successful Ad vector systems for cancer therapy, the chemical or physical modification of Ad vectors with polymers has been generally used as a promising strategy to overcome the obstacles. With polyethylene glycol (PEG) first in order, a variety of polymers have been developed to shield the surface of therapeutic Ad vectors and well accomplished to extend circulation time in blood and reduce liver toxicity. However, although polymer-coated Ads can successfully evacuate from a series of guarding systems in vivo and locate within tumors by enhanced permeability and retention (EPR) effect, the possibility to entering into the target cell is few and far between. To endow targeting moiety to polymer-coated Ad vectors, a diversity of ligands such as tumor-homing peptides, growth factors or antibodies, have been introduced with avoiding unwanted transduction and enhancing therapeutic efficacy. Here, we will describe and classify the characteristics of the published polymers with respect to Ad vectors. Furthermore, we will also compare the properties of variable targeting ligands, which are being utilized for addressing polymer-coated Ad vectors actively.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture10.3181/00379727-84-20714 ↗
2. Studies on the use of viruses in the treatment of carcinoma of the cervix10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7 ↗
3. History of oncolytic viruses: genesis to genetic engineering10.1038/sj.mt.6300108 ↗
4. Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report
5. Remote results of clinical observation of the oncolytic action of adenoviruses on cervix cancer
6. Adenovirus vectors: biology, design, and production
7. Modified adenoviruses for cancer gene therapy10.1002/ijc.20129 ↗
8. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells10.1126/science.274.5286.373 ↗
9. Conditionally replicating adenoviruses for cancer treatment10.2174/156800907780618301 ↗
10. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data10.1021/mp100219n ↗
11. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy10.1038/sj.cgt.7700494 ↗
12. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects10.1089/hum.2006.167 ↗
13. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
14. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells10.1016/S0304-3835(02)00017-4 ↗
15. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy
16. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen10.1172/JCI9180 ↗
17. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner10.1089/104303403769211637 ↗
18. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas10.1158/1078-0432.CCR-10-0664 ↗
19. Replicative adenoviruses for cancer therapy10.1038/77283 ↗
20. Safety evaluation of Ad5CMV-p53 in vitro and in vivo10.1089/hum.1995.6.2-155 ↗
21. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells
22. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine10.1089/hum.1995.6.8-1055 ↗
23. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis10.4049/jimmunol.165.5.2886 ↗
24. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect10.1038/sj.gt.3302759 ↗
25. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model10.1158/1078-0432.CCR-06-0935 ↗
26. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth10.1038/sj.mt.6300023 ↗
27. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition10.1038/gt.2008.3 ↗
28. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis10.1038/sj.cgt.7700769 ↗
29. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy10.1093/jnci/djj397 ↗
30. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy10.1038/gt.2009.142 ↗
31. Blood clearance rates of adenovirus type 5 in mice10.1099/0022-1317-81-11-2605 ↗
32. Head and neck cancer: gene therapy approaches. Part II: genes delivered10.1517/14712598.2.3.311 ↗
33. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo10.1089/10430349950018364 ↗
34. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages10.1006/mthe.2001.0329 ↗
35. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors10.1089/104303403321618146 ↗
36. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system10.1016/j.ymthe.2006.03.024 ↗
37. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma10.1089/hum.1998.9.14-2121 ↗
38. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein10.4049/jimmunol.174.11.7179 ↗
39. Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression10.1177/09680519040100060301 ↗
40. Passive tumor targeting of soluble macromolecules and drug conjugates
41. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
42. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide10.1038/sj.mt.6300321 ↗
43. HPMA copolymers for masking and retargeting of therapeutic viruses10.1016/j.addr.2009.12.003 ↗
44. Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity10.5483/BMBRep.2010.43.12.781 ↗
45. Engineering biomaterial systems to enhance viral vector gene delivery10.1038/mt.2011.111 ↗
46. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes10.1128/jvi.70.4.2116-2123.1996 ↗
47. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity10.1016/j.vaccine.2004.02.011 ↗
48. Targeted adenovirus vectors10.1089/hum.2004.15.1034 ↗
49. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo10.1089/10430349950018021 ↗
50. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector10.1038/sj.gt.3302875 ↗
51. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver10.1089/104303402760372972 ↗
52. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies10.1038/sj.gt.3301389 ↗
53. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses10.1016/j.ymthe.2004.09.015 ↗
54. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies10.1038/sj.mt.6300306 ↗
55. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression10.1038/mt.2008.86 ↗
56. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration10.1016/j.jconrel.2007.06.010 ↗
57. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis10.1038/gt.2009.95 ↗
58. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses10.1089/hum.2008.091 ↗
59. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review10.1186/1476-5926-1-1 ↗
60. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors10.1016/j.ymthe.2005.03.006 ↗
61. Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction10.1016/j.biomaterials.2010.10.060 ↗
62. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus10.1038/sj.gt.3302295 ↗
63. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy10.1080/10611860701501014 ↗
64. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components10.1016/j.jconrel.2008.12.009 ↗
65. Charge configurations in viral proteins10.1073/pnas.85.24.9396 ↗
66. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine10.1073/pnas.92.16.7297 ↗
67. Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery10.1038/sj.gt.3300471 ↗
68. Adenovirus enhancement of polyethylenimine-mediated transfer of regulated genes in differentiated cells10.1038/sj.gt.3300450 ↗
69. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity10.1023/A:1014861900478 ↗
70. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine10.1016/S0168-3659(03)00076-2 ↗
71. Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction10.1088/0957-4484/21/10/105106 ↗
72. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system10.1016/S0021-9258(18)61209-8 ↗
73. Current status of polymeric gene delivery systems10.1016/j.addr.2006.03.007 ↗
74. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo10.1074/jbc.272.10.6479 ↗
75. Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy10.1182/blood.V97.8.2221 ↗
76. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis10.1038/nm0195-39 ↗
77. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction10.1016/j.jconrel.2009.11.001 ↗
78. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro10.1038/sj.gt.3300665 ↗
79. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo10.1096/fj.08-103275 ↗
80. Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro10.1016/S0142-9612(02)00203-X ↗
81. Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy10.1016/j.jconrel.2010.06.027 ↗
82. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes10.1002/jgm.237 ↗
83. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems10.1208/aapsj080483 ↗
84. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes10.1074/jbc.M308643200 ↗
85. Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity10.1021/bc700397x ↗
86. Bioreducible polymers for efficient gene and siRNA delivery10.1088/1748-6041/4/2/025020 ↗
87. Influence of the molecular weight of bioreducible oligoethylenimine conjugates on the polyplex transfection properties10.1208/s12248-009-9122-3 ↗
88. Bioreducible polymers for gene delivery10.1016/j.reactfunctpolym.2010.11.016 ↗
89. Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems10.1016/j.biomaterials.2008.10.009 ↗
90. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy10.1016/j.biomaterials.2009.11.043 ↗
91. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration10.1016/j.biomaterials.2011.08.066 ↗
92. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA10.1016/j.biomaterials.2011.03.084 ↗
93. Biodegradable alginate microspheres as a delivery system for naked DNA
94. Oral vaccination of animals with antigens encapsulated in alginate microspheres10.1016/S0264-410X(98)00437-X ↗
95. Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata10.1016/S0169-409X(97)00055-0 ↗
96. Biodegradable nanoparticles for drug and gene delivery to cells and tissue10.1016/S0169-409X(02)00228-4 ↗
97. Current strategies and future directions for eluding adenoviral vector immunity10.2174/156652306776359478 ↗
98. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response10.1038/sj.gt.3301858 ↗
99. Sustained delivery of oncolytic adenovirus in alginate gel for local tumor virotheraphy10.1016/j.jconrel.2010.07.074 ↗
100. Microencapsulation of PEGylated adenovirus within PLGA microspheres for enhanced stability and gene transfection efficiency10.1007/s11095-007-9441-y ↗